Jan. 12, 2021

BioVersys reports first dosing of BVL-GSK098 in clinical Phase I

BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a great achievement for this groundbreaking program. For the first time, a small molecule targeting bacterial transcriptional regulators, is clinically assessed. We would like to thank our many partners in this program, especially our colleagues Nicolas Willand, Alain Baulard and Benoit Deprez from the University of Lille and Pasteur institute in Lille and all the colleagues at GSK.

Press Release